Vincristine

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`DRUG-VINCRISTINE`
Type	Drug
Aliases	OncovinVincasarВінкристин
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-AITL` `DIS-ATLL` `DIS-B-ALL` `DIS-BURKITT` `DIS-DLBCL-NOS` `DIS-EATL` `DIS-FL` `DIS-GLIOMA-LOW-GRADE` `DIS-HGBL-DH` `DIS-HSTCL` `DIS-MCL` `DIS-NLPBL` `DIS-PCNSL` `DIS-PMBCL` `DIS-PTCL-NOS` `DIS-PTLD` `DIS-T-ALL`
Sources	`SRC-NCCN-BCELL-2025`

Drug Facts

Class	antineoplastic — vinca alkaloid (microtubule inhibitor)
Mechanism	Binds tubulin, prevents microtubule polymerization, blocks mitotic spindle formation → arrests cells in metaphase, induces apoptosis.
Ukraine registered	True
NSZU reimbursed	True
Ukraine last verified	2026-04-27

Warnings

FATAL if administered intrathecally — must be packaged in mini-bag, never syringe, per WHO/FDA

Notes

Cap at 2 mg per dose (regardless of BSA) to limit neuropathy. Held or dose-reduced for grade ≥2 peripheral neuropathy. Hepatic dose adjustment for total bilirubin >3 mg/dL. WHO has issued repeated warnings about fatal accidental intrathecal administration — always packaged in IV mini-bag, never as a syringe.

Used By

Regimens

REG-CHOEP - CHOEP (cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone), 6 cycles
REG-CHOEP-ALLOSCT-CONSOLIDATION - CHOEP × 6 + allogeneic SCT consolidation in CR1 (fit transplant-eligible PTCL NOS)
REG-CODOX-M-IVAC - CODOX-M / IVAC alternating × 4 (Magrath protocol)
REG-DA-EPOCH-R - Dose-Adjusted EPOCH + Rituximab (DA-EPOCH-R), 6 cycles
REG-HYPER-CVAD-R - Hyper-CVAD + Rituximab (CD20+) — alternating courses A/B, 8 cycles total
REG-MCL-INTENSIVE-RDHAP-AUTOSCT - Intensive 1L MCL: alternating R-CHOP / R-DHAP × 6 cycles + autoSCT consolidation + R main...
REG-POMP-B-ALL-MAINTENANCE - POMP maintenance — B-ALL post-induction-consolidation (vincristine + 6-MP + MTX + prednis...
REG-R-CHOP - Rituximab + CHOP (R-CHOP), 6 cycles
REG-R-MPV - R-MPV (Rituximab + HD-Methotrexate + Procarbazine + Vincristine), 5 cycles q14d
REG-R-MPV-SALVAGE-PCNSL - Salvage HD-MTX-based re-induction for relapsed PCNSL
REG-RT-PCV-LGG - Radiotherapy + PCV (procarbazine/lomustine/vincristine) — high-risk low-grade glioma